Sarepta Therapeutics (SRPT) EPS Estimated At $-0.92; Unilever NV (ADR) (UN) Had 5 Analysts Last Week

July 18, 2017 - By Richard Conner

Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to report $-0.92 EPS on July, 19 after the close.They anticipate $0.42 EPS change or 31.34% from last quarter’s $-1.34 EPS. After having $-0.73 EPS previously, Sarepta Therapeutics Inc’s analysts see 26.03% EPS growth. The stock decreased 0.85% or $0.3 during the last trading session, reaching $34.95. About shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since July 18, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Among 9 analysts covering Unilever NV (NYSE:UN), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Unilever NV had 10 analyst reports since September 25, 2015 according to SRatingsIntel. The rating was downgraded by RBC Capital Markets on Friday, July 22 to “Sector Perform”. The stock has “Buy” rating by Berenberg on Friday, September 25. The rating was downgraded by JP Morgan to “Neutral” on Wednesday, December 7. Liberum Capital reinitiated the stock with “Hold” rating in Monday, March 27 report. The firm has “Overweight” rating by Barclays Capital given on Friday, March 24. Bernstein initiated the stock with “Outperform” rating in Monday, August 22 report. The firm earned “Buy” rating on Wednesday, August 31 by Citigroup. The firm has “Overweight” rating given on Tuesday, January 12 by JP Morgan. Jefferies upgraded the shares of UN in report on Tuesday, December 13 to “Buy” rating. The rating was upgraded by Credit Suisse to “Neutral” on Tuesday, December 8. See Unilever NV (ADR) (NYSE:UN) latest ratings:

27/03/2017 Broker: Liberum Capital Rating: Hold Reinitiate
24/03/2017 Broker: Barclays Capital Old Rating: Equal Weight New Rating: Overweight Upgrade

Unilever N.V. is a fast-moving consumer goods company. The company has market cap of $168.57 billion. The Company’s divisions include Personal Care, which primarily includes sales of skin care and hair care products, deodorants and oral care products; Foods, which primarily includes sales of soups, bouillons, sauces, snacks, mayonnaise, salad dressings, margarines and spreads; Home Care, which primarily includes sales of home care products, such as powders, liquids and capsules, soap bars and a range of cleaning products, and Refreshment, which primarily includes sales of ice cream and tea beverages. It has a 27.28 P/E ratio. The Company’s geographical divisions include Asia/AMET/RUB, The Americas and Europe.

The stock decreased 0.02% or $0.01 during the last trading session, reaching $56.87. About 2,000 shares traded. Unilever NV (ADR) (NYSE:UN) has risen 26.55% since July 18, 2016 and is uptrending. It has outperformed by 9.85% the S&P500.

Investors sentiment decreased to 1.07 in 2016 Q4. Its down 0.45, from 1.52 in 2016Q3. It worsened, as 42 investors sold Sarepta Therapeutics Inc shares while 46 reduced holdings. 39 funds opened positions while 55 raised stakes. 38.63 million shares or 7.09% less from 41.57 million shares in 2016Q3 were reported. Venbio Select Advisor invested in 5.6% or 1.01 million shares. Wells Fargo & Mn holds 0% or 68,090 shares in its portfolio. Goldman Sachs Grp reported 238,363 shares. Fmr Lc invested in 0% or 1.20 million shares. Interest Group Inc owns 24,574 shares or 0% of their US portfolio. Raymond James & invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). 2.01M were reported by Sabby Mgmt Limited Company. Morgan Stanley has invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Brown Brothers Harriman And invested 0% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Illinois-based Hightower Limited Liability Corp has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Deutsche Bank & Trust Ag owns 314,364 shares. Hap Trading Ltd Liability Co reported 36,556 shares. Quantitative Inv Limited Liability Co invested in 0.14% or 197,400 shares. Voya Invest Management Lc reported 19,699 shares. Spot Trading Limited Liability Company stated it has 13,631 shares or 0.01% of all its holdings.

Among 24 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Sarepta Therapeutics had 65 analyst reports since August 5, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of SRPT in report on Wednesday, June 28 with “Buy” rating. The company was upgraded on Monday, August 24 by Piper Jaffray. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Wednesday, September 28 by RBC Capital Markets. On Friday, October 23 the stock rating was initiated by Jefferies with “Hold”. The firm has “Neutral” rating by Janney Capital given on Wednesday, April 20. As per Wednesday, March 1, the company rating was maintained by RBC Capital Markets. Roth Capital maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Thursday, August 20. Roth Capital has “Buy” rating and $45 target. The rating was initiated by JP Morgan with “Overweight” on Thursday, December 22. The rating was maintained by Oppenheimer on Wednesday, June 7 with “Buy”. The firm earned “Buy” rating on Tuesday, August 25 by Vetr.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: